AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents for cancer and cardiovascular disease diagnosis. The company's commercial products, Feridex I.V. and GastroMARK, are approved and marketed in the United States, Europe, and other countries. Their key product candidate, Ferumoxytol, is being developed for intravenous iron replacement therapy in chronic kidney disease, while Combidex is an investigational imaging agent for use with MRI to differentiate cancerous from normal lymph nodes. The company's corporate and executive offices are located in Cambridge, Mass.